PAVmed Inc. (PAVM)
PAVMNASDAQ-CMMedical/Dental Instruments
$1.63
0.0000 (0.00%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $1.62 -1.82%
- Market cap
- $13.03m
- P/E
- –
- EPS, last 4 quarters
- $-14.91
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.53 to $28.44
- Average volume
- 21.2k
- Previous close
- $1.63
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $36.50, +2139.3% from here
Earnings
next estimate $-1.02Next report Nov 13, 2026
Sep 2025
-38.0%
Dec 2025
+72.7%
Mar 2026
-458.8%
Jun 2026
+36.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $5,000 | $52.0k | $22.0k | $33.0k |
| Gross profit | -$50.0k | -$33.0k | -$75.0k | -$89.0k |
| Operating income | -$4.84m | -$6.80m | -$8.04m | -$7.02m |
| Net income | -$5.38m | -$1.26m | -$60.0k | -$5.38m |
Last four quarters: revenue $112.0k, margin -10794.6%, free cash flow -$7.78m
News
8 latest- PAVmed Inc. Subsidiary Lucid Diagnostics Raises $15.0 million in Series C Preferred Stock OfferingFintel · Oct 22, 2026
- Lucid Shares Jump 40% Overnight On EsoGuard Medicare Payments, $15 Mln Financing RTTNews · Oct 22, 2026
- PAVmed (PAVM) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 14, 2026
- Pre-Market Earnings Report for August 14, 2026 : USAS, SGML, OTLK, STRR, PAVM, LFWD, CMCT, QNRX, ACXPNASDAQ.com · Aug 13, 2026
- PAVmed (PAVM) Q1 2026 Earnings TranscriptThe Motley Fool · May 15, 2026
- PAVmed (PAVM) Q4 2025 Earnings TranscriptThe Motley Fool · May 15, 2026
- PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue EstimatesZacks · May 15, 2026
- Pre-Market Earnings Report for May 15, 2026 : RBC, HTHT, SGML, SPRY, AZ, LUCD, MHH, INKT, PAVM, SURG, LFWD, SLENASDAQ.com · May 14, 2026
The company
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device-the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- pavmed.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.